Search

Mapping the Journey of Australian Paediatric Low‑Grade Glioma (pLGG) Patients

HomeCase StudiesMapping the Journey of Australian Paediatric Low‑Grade Glioma (pLGG) Patients

Biointelect supported an Australian‑first qualitative research project to map the lived experience of children and families navigating paediatric low‑grade glioma (pLGG). Drawing on in‑depth interviews with Australian pLGG families and treating clinicians, the project developed a Patient Journey Map capturing key stages from early symptom recognition and diagnosis through treatment, survivorship, and transition to adult care.

The work highlights significant variability in patient pathways, common challenges such as diagnostic delays and access to therapies, and the long‑term quality‑of‑life impacts of living with pLGG. Designed as both a family support resource and an advocacy tool, the Patient Journey Map translates lived experience into practical insights to inform more holistic, patient‑centred care in Australia.

Related Resources

Want To Find Out More?

Are you interested in learning more about Biointelect, including our current white paper submissions and health policy related work?

Get in touch with our team to discover how we’re advancing healthcare for all and how you can harness our intellect and proven expertise in bringing innovative life science to market.

Eri Nishiuchi

Strategic Development and Business Effectiveness

Eri Nishiuchi holds a Bachelor of Business degree from the University of Technology Sydney. Her expertise lies in health systems analysis and client relationship management within the healthcare and life sciences sectors. She also has experience working with patient organisations.

Throughout her career, Eri has provided competitive landscape research support to pharmaceutical and biotech clients across the Asia Pacific region, achieving one of the top client retention rates in the region. Her multilingual abilities have been instrumental in fostering strong relationships with diverse stakeholders.

Eri joined Biointelect in 2024 in a strategic development and business effectiveness role, where her focus will be on conducting market analysis and improving business processes.